Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

About Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals logoEagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EGRX
  • CUSIP: N/A
  • Web: www.eagleus.com
  • Market Cap: $753.3 million
  • Outstanding Shares: 15,169,000
Average Prices:
  • 50 Day Moving Avg: $56.96
  • 200 Day Moving Avg: $69.64
  • 52 Week Range: $45.05 - $97.15
  • Trailing P/E Ratio: 8.33
  • Foreward P/E Ratio: 12.98
  • P/E Growth: 0.91
Sales & Book Value:
  • Annual Revenue: $245.88 million
  • Price / Sales: 3.06
  • Book Value: $10.90 per share
  • Price / Book: 4.55
  • EBITDA: $83.99 million
  • Net Margins: 39.32%
  • Return on Equity: 66.30%
  • Return on Assets: 48.44%
  • Current Ratio: 3.88%
  • Quick Ratio: 3.76%
  • Average Volume: 394,417 shs.
  • Beta: 1.31
  • Short Ratio: 8.68

Frequently Asked Questions for Eagle Pharmaceuticals (NASDAQ:EGRX)

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How will Eagle Pharmaceuticals' stock buyback program work?

Eagle Pharmaceuticals declared that its board has initiated a share buyback plan on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 13.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings data on Wednesday, August, 9th. The company reported $0.33 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.18. The company had revenue of $50.10 million for the quarter, compared to analysts' expectations of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.80 earnings per share. View Eagle Pharmaceuticals' Earnings History.

Where is Eagle Pharmaceuticals' stock going? Where will Eagle Pharmaceuticals' stock price be in 2017?

4 analysts have issued 1-year price objectives for Eagle Pharmaceuticals' stock. Their predictions range from $37.00 to $97.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $72.50 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

What are analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/31/2017)
  • 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)

Who are some of Eagle Pharmaceuticals' key competitors?

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:

  • Michael Graves, Independent Chairman of the Board
  • Scott L. Tarriff, Chief Executive Officer, Independent Director
  • Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
  • David E. Riggs, Chief Financial Officer
  • Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
  • Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer
  • Douglas L. Braunstein, Independent Director
  • Richard A. Edlin, Independent Director
  • Sander A. Flaum, Independent Director
  • Robert L. Glenning, Independent Director

Who owns Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.04%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Who bought Eagle Pharmaceuticals stock? Who is buying Eagle Pharmaceuticals stock?

Eagle Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy Eagle Pharmaceuticals stock?

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $49.60.

MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)
Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eagle Pharmaceuticals (NASDAQ:EGRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $72.50 (46.17% upside)
Consensus Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Price Target History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Analysts' Ratings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017MizuhoLower Price TargetUnderperform -> Underperform$40.00 -> $37.00HighView Rating Details
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$75.00MediumView Rating Details
7/27/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$94.00 -> $81.00MediumView Rating Details
11/2/2016William BlairBoost Price TargetOutperform$83.00 -> $97.00N/AView Rating Details
(Data available from 10/19/2015 forward)


Earnings History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Earnings by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Earnings History by Quarter for Eagle Pharmaceuticals (NASDAQ EGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017$0.51$0.33$52.52 million$50.10 millionViewListenView Earnings Details
5/8/2017Q1 2017$1.44$1.42$70.10 million$76.80 millionViewListenView Earnings Details
3/1/2017Q416$2.24$3.52$86.13 million$81.10 millionViewListenView Earnings Details
11/9/2016Q316$0.71$0.73$41.04 million$37.80 millionViewListenView Earnings Details
8/9/2016Q216$0.71$0.80$43.55 million$40.90 millionViewN/AView Earnings Details
5/9/2016Q116$0.46($0.06)$29.07 million$29.60 millionViewN/AView Earnings Details
2/25/2016Q415$0.53$0.07$20.78 million$18.20 millionViewListenView Earnings Details
11/11/2015Q315($0.56)($0.65)$5.07 million$3.30 millionViewListenView Earnings Details
8/11/2015Q215($0.59)($0.53)$4.70 million$6.00 millionViewListenView Earnings Details
5/12/2015Q115$1.56$1.31$3.41 million$36.30 millionViewListenView Earnings Details
12/17/2014Q314($0.49)($0.65)$2.90 million$2.81 millionViewN/AView Earnings Details
8/11/2014Q214($0.39)($0.21)$3.40 million$5.80 millionViewN/AView Earnings Details
5/14/2014Q114($0.26)($0.36)$3.20 million$5.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)
2017 EPS Consensus Estimate: $3.82
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$1.46$1.46$1.46
Q2 20171$0.59$0.59$0.59
Q3 20171$0.76$0.76$0.76
Q4 20171$1.01$1.01$1.01
(Data provided by Zacks Investment Research)


Dividend History for Eagle Pharmaceuticals (NASDAQ:EGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Ownership Percentage: 19.50%
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Insider Trades by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/16/2017Pete A MeyersCFOBuy350$55.45$19,407.50View SEC Filing  
8/9/2017Douglas L BraunsteinDirectorBuy20,400$49.07$1,001,028.00View SEC Filing  
6/12/2017Pete A MeyersCFOBuy350$71.49$25,021.50View SEC Filing  
5/19/2017David PernockInsiderBuy255$79.69$20,320.95View SEC Filing  
5/16/2017David PernockInsiderBuy200$82.24$16,448.00View SEC Filing  
4/25/2017Proquest Investments Iv, L.P.Major ShareholderSell54,180$88.38$4,788,428.40View SEC Filing  
4/3/2017Proquest Investments Iv, L.P.Major ShareholderSell91,332$83.09$7,588,775.88View SEC Filing  
3/29/2017Proquest Investments Iv, L.P.Major ShareholderSell106,468$83.01$8,837,908.68View SEC Filing  
3/28/2017Proquest Investments Iv, L.P.Major ShareholderSell6,182$83.02$513,229.64View SEC Filing  
3/27/2017Proquest Investments Iv, L.P.Major ShareholderSell39,431$83.00$3,272,773.00View SEC Filing  
3/23/2017Proquest Investments Iv, L.P.Major ShareholderSell1,200$83.05$99,660.00View SEC Filing  
3/23/2017Steven L KrillEVPSell14,125$81.07$1,145,113.75View SEC Filing  
3/22/2017Richard A EdlinDirectorBuy6,000$79.44$476,640.00View SEC Filing  
3/21/2017David PernockInsiderBuy61$83.98$5,122.78View SEC Filing  
3/20/2017Proquest Investments Iv, L.P.Major ShareholderSell100,000$82.06$8,206,000.00View SEC Filing  
3/9/2017David PernockInsiderBuy450$77.84$35,028.00View SEC Filing  
1/4/2017Proquest Investments Iv, L.P.Major ShareholderSell65,114$85.16$5,545,108.24View SEC Filing  
12/13/2016Steven B RatoffDirectorSell10,000$75.01$750,100.00View SEC Filing  
11/28/2016Sander A FlaumDirectorSell5,000$78.66$393,300.00View SEC Filing  
11/11/2016Proquest Investments Iv, L.P.Major ShareholderSell34,486$85.15$2,936,482.90View SEC Filing  
11/9/2016Proquest Investments Iv, L.P.Major ShareholderSell153,830$79.29$12,197,180.70View SEC Filing  
11/7/2016Proquest Investments Iv, L.P.Major ShareholderSell5,030$75.39$379,211.70View SEC Filing  
11/4/2016Proquest Investments Iv, L.P.Major ShareholderSell245,770$71.02$17,454,585.40View SEC Filing  
9/30/2016Proquest Investments Iv, L.P.Major ShareholderSell22,100$70.06$1,548,326.00View SEC Filing  
9/29/2016Proquest Investments Iv, L.P.Major ShareholderSell77,900$70.04$5,456,116.00View SEC Filing  
9/21/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$66.17$6,603,435.15View SEC Filing  
9/8/2016Proquest Investments Iv, L.P.Major ShareholderSell70,925$62.50$4,432,812.50View SEC Filing  
8/24/2016Proquest Investments Iv, L.P.Major ShareholderSell28,870$63.00$1,818,810.00View SEC Filing  
8/17/2016Proquest Investments Iv, L.P.Major ShareholderSell99,795$61.36$6,123,421.20View SEC Filing  
8/16/2016Proquest Investments Iv, L.P.Major ShareholderSell60,150$61.67$3,709,450.50View SEC Filing  
8/15/2016Proquest Investments Iv, L.P.Major ShareholderSell24,949$60.77$1,516,150.73View SEC Filing  
5/13/2016Proquest Management LlcMajor ShareholderSell17,980$40.72$732,145.60View SEC Filing  
4/1/2016Scott TarriffCEOSell30,765$40.63$1,249,981.95View SEC Filing  
3/15/2016Michael GravesDirectorBuy1,000$56.73$56,730.00View SEC Filing  
2/1/2016Scott TarriffCEOSell18,360$68.08$1,249,948.80View SEC Filing  
12/22/2015Sander A. FlaumDirectorSell13,025$54.81$713,900.25View SEC Filing  
12/1/2015Scott TarriffCEOSell14,050$88.93$1,249,466.50View SEC Filing  
11/2/2015Scott TarriffCEOSell19,339$64.63$1,249,879.57View SEC Filing  
10/1/2015Scott TarriffCEOSell17,878$69.92$1,250,029.76View SEC Filing  
9/1/2015Scott TarriffCEOSell16,245$76.95$1,250,052.75View SEC Filing  
7/1/2015Scott TarriffCEOSell135,710$46.34$6,288,801.40View SEC Filing  
6/16/2015Steven L KrillInsiderSell9,980$81.60$814,368.00View SEC Filing  
2/18/2014Jay MoorinDirectorBuy333,333$15.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Eagle Pharmaceuticals (NASDAQ:EGRX)
Latest Headlines for Eagle Pharmaceuticals (NASDAQ:EGRX)
americanbankingnews.com logoBrokers Issue Forecasts for Eagle Pharmaceuticals, Inc.'s Q4 2017 Earnings (EGRX)
www.americanbankingnews.com - October 18 at 11:20 AM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Reports New Patent for RYANODEX - StreetInsider.com
www.streetinsider.com - October 17 at 11:59 PM
finance.yahoo.com logoEagle Pharmaceuticals Announces New Patent for RYANODEX
finance.yahoo.com - October 17 at 6:58 PM
nasdaq.com logoEagle Pharmaceuticals is Now Oversold - Nasdaq
www.nasdaq.com - October 16 at 9:23 PM
finance.yahoo.com logo3 Biotech Values in a Fully Valued Market
finance.yahoo.com - October 15 at 5:30 PM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:46 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : EGRX-US : October 11, 2017
finance.yahoo.com - October 11 at 7:46 PM
americanbankingnews.com logoContrasting Eagle Pharmaceuticals (EGRX) & The Competition
www.americanbankingnews.com - October 9 at 10:24 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 10:44 AM
americanbankingnews.com logoReviewing Supernus Pharmaceuticals (SUPN) & Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - October 6 at 6:24 AM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 10:58 AM
americanbankingnews.com logoAnalyzing Eagle Pharmaceuticals (EGRX) and Its Competitors
www.americanbankingnews.com - September 28 at 8:30 PM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. :EGRX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 25, 2017
finance.yahoo.com - September 25 at 11:26 AM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) versus Its Rivals Head-To-Head Survey
www.americanbankingnews.com - September 24 at 8:10 PM
prnewswire.com logoDaily Technical Summary Reports on Generic Drugs Stocks ... - PR Newswire (press release)
www.prnewswire.com - September 22 at 8:38 AM
finance.yahoo.com logoCorporate News Blog - Eagle Pharma’s Licenses Japanese Rights to SymBio Pharma for Bendamustine HCl Ready-to-dilute and Rapid Infusion Injection Products
finance.yahoo.com - September 22 at 8:38 AM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Reports Agreement to License Japanese Rights for Bendamustine Hydrochlorid - StreetInsider.com
www.streetinsider.com - September 20 at 7:07 PM
finance.yahoo.com logoETFs with exposure to Eagle Pharmaceuticals, Inc. : September 20, 2017
finance.yahoo.com - September 20 at 4:13 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. – Value Analysis (NASDAQ:EGRX) : September 19, 2017
finance.yahoo.com - September 19 at 11:09 PM
americanbankingnews.com logoFinancial Comparison: Eagle Pharmaceuticals (EGRX) versus TherapeuticsMD (TXMD)
www.americanbankingnews.com - September 19 at 6:30 AM
americanbankingnews.com logoHead-To-Head Analysis: Eagle Pharmaceuticals (EGRX) & AbbVie (ABBV)
www.americanbankingnews.com - September 19 at 2:20 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : EGRX-US : September 18, 2017
finance.yahoo.com - September 18 at 6:04 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) and Its Competitors Financial Review
www.americanbankingnews.com - September 18 at 2:30 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) vs. Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - September 17 at 6:16 AM
americanbankingnews.com logoReviewing Eagle Pharmaceuticals (EGRX) & Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - September 16 at 6:14 AM
americanbankingnews.com logoContrasting Eagle Pharmaceuticals (EGRX) and AbbVie (ABBV)
www.americanbankingnews.com - September 15 at 12:36 PM
americanbankingnews.com logoReviewing Eagle Pharmaceuticals (EGRX) and The Competition
www.americanbankingnews.com - September 14 at 2:22 AM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 13 at 10:40 AM
americanbankingnews.com logoFinancial Contrast: Advanced Accelerator Applications (AAAP) versus Eagle Pharmaceuticals (EGRX)
www.americanbankingnews.com - September 13 at 10:16 AM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) and Aimmune Therapeutics (AIMT) Head to Head Review
www.americanbankingnews.com - September 12 at 9:02 AM
businesswire.com logoEagle Pharmaceuticals, Inc. to Present at September Investor Conferences - Business Wire (press release)
www.businesswire.com - September 7 at 4:18 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc. to Present at September Investor Conferences
finance.yahoo.com - September 6 at 6:11 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Price Target Cut to $37.00 by Analysts at Mizuho
www.americanbankingnews.com - September 6 at 9:17 AM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Reports Positive Results of Study Conducted to Evaluate Neuroprotective Effects of ... - StreetInsider.com
www.streetinsider.com - September 6 at 5:54 AM
streetinsider.com logoEagle Pharmaceuticals (EGRX) Reports Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX
www.streetinsider.com - September 5 at 7:49 PM
finance.yahoo.com logoEagle Pharmaceuticals Announces Positive Results of Study Conducted to Evaluate Neuroprotective Effects of RYANODEX Secondary to Nerve Agent Exposure
finance.yahoo.com - September 5 at 7:49 PM
seekingalpha.com logoEagle Pharmaceuticals: Strong Upside Potential Despite Recent Heatstroke Stumble - Seeking Alpha
seekingalpha.com - September 2 at 5:26 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) and Rockwell Medical (RMTI) Financial Survey
www.americanbankingnews.com - August 30 at 8:16 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) & Repligen Corporation (RGEN) Head-To-Head Comparison
www.americanbankingnews.com - August 20 at 4:22 AM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 19 at 10:50 AM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) CFO Purchases $19,407.50 in Stock
www.americanbankingnews.com - August 16 at 10:44 PM
americanbankingnews.com logoContrasting Eagle Pharmaceuticals (EGRX) and Macrocure (MCUR)
www.americanbankingnews.com - August 16 at 2:10 AM
finance.yahoo.com logoEagle Pharmaceuticals, Inc.: Sudden move in price, will it continue?
finance.yahoo.com - August 14 at 6:35 PM
americanbankingnews.com logoWilliam Blair Equities Analysts Lift Earnings Estimates for Eagle Pharmaceuticals, Inc. (EGRX)
www.americanbankingnews.com - August 14 at 3:18 AM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (EGRX) Director Douglas L. Braunstein Acquires 20,400 Shares
www.americanbankingnews.com - August 11 at 7:26 PM
americanbankingnews.com logoEagle Pharmaceuticals Inc (EGRX) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 8:02 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Eagle Pharmaceuticals Inc.
finance.yahoo.com - August 10 at 7:27 PM
americanbankingnews.com logoEagle Pharmaceuticals (EGRX) Board Initiates Share Repurchase Plan
www.americanbankingnews.com - August 10 at 12:20 PM
americanbankingnews.com logoEagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Given a $75.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - August 10 at 9:08 AM
finance.yahoo.com logoEdited Transcript of EGRX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 9 at 11:25 PM



Eagle Pharmaceuticals (EGRX) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.